Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2416 to 2430 of 7681 results

  1. Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]

    In development [GID-TA10904] Expected publication date: 15 January 2025

    Technology appraisal guidance
    In development

  2. Linzagolix for treating symptoms of endometriosis [ID6357]

    In development [GID-TA11376] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  3. Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897

    In development [GID-TA11437] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Acne

    Awaiting development [GID-QS10036] Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Primary hyperparathyroidism

    Awaiting development [GID-QS10089] Expected publication date: TBC

    Quality standard
    Awaiting development

  6. School-based interventions: physical and mental health and wellbeing promotion

    In development [GID-QS10070] Expected publication date: TBC

    Quality standard
    In development

  7. NVK-002 for treating myopia in people 3 to 17 years TSID 11961

      Status ...

    Technology appraisal guidance
    Topic selection

  8. Guselkumab for previously treated moderately to severely active Crohn's disease ID6238

    In development [GID-TA11245] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Guselkumab for treating moderately to severely active ulcerative colitis ID6237

    In development [GID-TA11247] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

    In development [GID-TA10990] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  11. Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]

    In development [GID-TA11514] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer [ID6220]

    In development [GID-TA11197] Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Laparoscopic insertion of a non-active implant for gastro-oesophageal reflux disease

    In development [GID-IPG10345] Expected publication date: 17 April 2025

    Interventional procedures guidance
    In development

  14. Gambling-related harms: identification, assessment and management

    In development [GID-NG10210] Expected publication date: TBC

    NICE guideline
    In development

  15. Drug-eluting coronary stents for treating coronary artery disease: late-stage assessment

    In development [GID-HTE10039] Expected publication date: 12 May 2025

    Health technology evaluations
    In development